Compare Synopsys, Inc. (SNPS) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs Tempus AI — how do they compare? Synopsys, Inc. trades at $509.81 (market cap $95.39B), while Tempus AI trades at $71 (market cap $12.58B). The key difference: Synopsys, Inc. is far larger — about 7.6× Tempus AI's market cap, and Synopsys, Inc. is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Synopsys, Inc. for 71 Days and Tempus AI for 23 Days on average.
| SNPS | TEM | |
|---|---|---|
Market Cap | $95.39B | $12.58B |
Volume | 3,374,903 | 7,444,569 |
Sector | Technology | Broad Market / Factor |
52-Week High | $534.56 | $99.28 |
52-Week Low | $367.70 | $41.55 |
Typical Hold Time | 71 Days | 23 Days |
Enterprise Value | $102.62B | $13.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) stock trades at $505.76, up 0.61% today, near its 52-week high. The technical picture is bullish with strong moving average support, though RSI levels suggest overbought conditions. Fundamentally, the company reported strong quarterly earnings beats and robust revenue growth, driven by AI partnerships with OpenAI and Amazon. Analyst sentiment is overwhelmingly positive with a 93% buy rating and a consensus price target of $572.54, indicating significant upside potential.
The outlook for SNPS is highly favorable, supported by AI-driven demand for chip design software and strategic acquisitions like Ansys. Key risks include high valuation multiples and integration challenges from recent deals. Investors should focus on execution of growth initiatives and monitor competitive pressures in the semiconductor design software market.
Tempus AI (TEM) trades at $71.46, up 1.66% with a bullish technical signal despite negative profitability metrics. The stock shows strong analyst support with 9 buy ratings and a $72.60 consensus target. Recent FDA clearance for ECG-MR AI product and 13 ESMO Congress presentations highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist at -$254M.
Outlook remains cautiously optimistic given strong institutional backing and AI healthcare growth potential, but profitability challenges and insider selling present near-term risks. The stock's valuation appears stretched with P/S of 8.61 and P/B of 28.27, requiring sustained revenue acceleration to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
